{"title":"Tirzepatide: Revolutionary Drug in Management of “Diabesity”","authors":"Vansh Chouhan, Simran Spal, Rakesh Kumar","doi":"10.18311/ijmds/2022/636","DOIUrl":null,"url":null,"abstract":"Tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist has recently been approved by FDA for type 2 diabetes in adults as a single dose weekly. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity. Tirzepatide is also under evaluation for treatment of non-alcoholic steatohepatitis, heart faialure and obstructive sleep apnea.","PeriodicalId":14010,"journal":{"name":"International Journal of Medical and Dental Sciences","volume":"62 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Medical and Dental Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18311/ijmds/2022/636","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Tirzepatide, a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist has recently been approved by FDA for type 2 diabetes in adults as a single dose weekly. Tirzepatide is in phase 3 development for adults with obesity or overweight with weight-related comorbidity. Tirzepatide is also under evaluation for treatment of non-alcoholic steatohepatitis, heart faialure and obstructive sleep apnea.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
